Consequently, we tried to investigate whether SP1, miR-421, and KDM2A interacted with TUG1 to promote cancerogenesis in CRC, hoping to uncover novel therapeutic targets against CRC. The gene discussed is KDM2A; the disease is colorectal carcinoma.